Der Nervenarzt

, Volume 77, Issue 6, pp 722–728 | Cite as

EURAP

Das europäische Register für Schwangerschaften unter Antiepileptika
Aktuelles

Zusammenfassung

Alle konventionellen Antiepileptika (AED) gelten als teratogen. In Deutschland nimmt eine von 200 schwangeren Frauen (0,5%) wegen einer Epilepsie AED ein. Das Risiko für große Fehlbildungen nach AED-Exposition im 1. Trimenon ist 2- bis 3fach gegenüber dem allgemeinen Fehlbildungsrisiko, das bei etwa 2–3% liegt, erhöht. Eine zuverlässige Information über substanzspezifische teratogene Risiken ist deshalb von großer Bedeutung für die Beratung von epilepsiekranken Frauen mit Schwangerschaftswunsch. Leider sind die vorliegenden Daten zum relativen Risiko von AED widersprüchlich, primär aufgrund zu kleiner Fallzahlen und methodischer Schwächen der existierenden Studien. Die teratogenen Risiken der so genannten neuen AED sind bisher kaum untersucht, weshalb derzeit keine rational begründeten Empfehlungen zur optimalen AED-Therapie in der Schwangerschaft existieren. EURAP (europäisches Register für Schwangerschaften unter AED) ist eine internationale prospektive Studie zur Erfassung großer Fehlbildungen bei Schwangerschaften unter AED-Exposition. In Deutschland wurden seit Beginn des Projektes 2001 über 500 Schwangerschaften rekrutiert. Bei einer geschätzten Zahl von jährlich 4000 Schwangerschaften unter AED-Exposition in Deutschland liegt die Rekrutierungsrate aktuell bei 4%.

Schlüsselwörter

Antiepileptika Teratogenität Schwangerschaftsregister EURAP 

EURAP

The European Registry of Antiepileptic Drugs and Pregnancy

Summary

All old-generation antiepileptic drugs (AEDs) are considered to be teratogenic. In Germany, one out of 200 pregnant women (0.5%) is treated with AEDs for epilepsy. The risk of major malformations following exposure to AEDs during the first trimester of pregnancy is two to three times the rate reported in the general population, which is estimated at 2‒3%. The risks associated with the treatment of epilepsy during pregnancy are therefore of major concern to all women of childbearing potential with epilepsy. Data on the comparative teratogenicity of these AEDs in humans are, however, conflicting, mainly due to inadequate sample sizes and other methodological shortcomings of previous studies. The teratogenic potential of newer AEDs is even less well known, which prevents a rational approach to AED treatment in women of childbearing potential. The European Registry of Antiepileptic Drugs and Pregnancy is a prospective international multicentre study of pregnancies with AEDs. In Germany the project was started in 2001 and so far more than 500 pregnancies have been enrolled. The enrollment rate is 4% of 4,000 pregnancies with AEDs reported annually.

Keywords

Antiepileptic drugs Teratogenicity Pregnancy registry European Registry of Antiepileptic Drugs and Pregnancy 

Literatur

  1. 1.
    Adab N, Jacoby A, Smith D et al. (2001) Additional educational needs in children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 70:15–21CrossRefPubMedGoogle Scholar
  2. 2.
    Adab N, Kini U, Vinten J et al. (2004) The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 75:1575–1583CrossRefPubMedGoogle Scholar
  3. 3.
    Alsdorf R, Wyszynski DF (2005) Teratogenicity of sodium valproate. Expert Opin Drug Saf 4:345–353CrossRefPubMedGoogle Scholar
  4. 4.
    Artama M, Auvinen A, Raudaskoski T et al. (2005) Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology 64:1874–1878PubMedGoogle Scholar
  5. 5.
    Cunnington M, Tennis P, the International Lamotrigine Pregnancy Registry Scientific Advisory Committee (2005) Lamotrigine and the risk of malformations during pregnancy. Neurology 64:955–960PubMedGoogle Scholar
  6. 6.
    DiLiberti JH, Farndon PA, Dennis NR et al. (1984) The fetal valproate syndrome. Am J Med Genet 19:473–481CrossRefPubMedGoogle Scholar
  7. 7.
    Eriksson K, Viinikainen K, Monkkonen A et al. (2005) Children exposed to valproate in utero—population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Res 65:189–200CrossRefPubMedGoogle Scholar
  8. 8.
    Gaily E, Kantola-Sorsa E, Hiilesmaa V et al. (2004) Normal intelligence in children with prenatal exposure to carbamazepine. Neurology 62:28–32PubMedGoogle Scholar
  9. 9.
    Hanson JW, Smith DW (1975) The fetal hydantoin syndrome. J Pediatr 87:285–290CrossRefPubMedGoogle Scholar
  10. 10.
    Hiilesmaa VK (1992) Pregnancy and birth in women with epilepsy. Neurology 42(Suppl 5):8–11Google Scholar
  11. 11.
    Holmes LB, Wyszynski DF (2004) North American antiepileptic drug pregnancy registry. Epilepsia 45:1465CrossRefPubMedGoogle Scholar
  12. 12.
    Holmes LB, Wyszynski DF, Lieberman E et al. (2004) The AED (Antiepileptic Drug) pregnancy registry. A 6-year experience. Arch Neurol 61:673–678CrossRefPubMedGoogle Scholar
  13. 13.
    Kallen B (1994) Maternal carbamazepine and infant spina bifida. Reprod Toxicol 8:203–205CrossRefPubMedGoogle Scholar
  14. 14.
    Kaneko S, Battino D, Andermann E et al. (1999) Congenital malformations due to antiepileptic drugs. Epilepsy Res 33:145–158CrossRefPubMedGoogle Scholar
  15. 15.
    Kersting M, Dulon M (2002) Assessment of breast-feeding promotion in hospitals and follow-up survey of mother-infant pairs in Germany: the SuSe Study. Public Health Nutr 5:547–552CrossRefPubMedGoogle Scholar
  16. 16.
    Lindhout D, Schmidt D (1986) In-utero exposure to valproate and neural tube defects. Lancet 1:1392–1393CrossRefPubMedGoogle Scholar
  17. 17.
    Lindhout D, Omtzigt JG, Cornel MC (1992) Spectrum of neural tube defects in 34 infants prenatally exposed to antiepileptic drugs. Neurology 42(Suppl 5):111–118Google Scholar
  18. 18.
    Lindhout D, Omtzigt JG (1994) Teratogenic effects of antiepileptic drugs: implications for the management of epilepsy in women of childbearing age. Epilepsia 35(Suppl 4):S19–S28Google Scholar
  19. 19.
    Little BB, Santos-Ramos R, Newell JF et al. (1993) Megadose carbamazepine during the period of neural tube closure. Obstet Gynecol 82(4 pt 2 Suppl):705–708Google Scholar
  20. 20.
    Morrow J, Russell A, Guthrie E et al. (2005) Malformation risks of anti-epileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 77:193–198CrossRefPubMedGoogle Scholar
  21. 21.
    Nelson K, Holmes LB (1989) Malformations due to presumed spontaneous mutations in newborn infants. N Engl J Med 320:19–23PubMedGoogle Scholar
  22. 22.
    Robert E, Guibaud P (1982) Maternal valproic acid and congenital neural tube defects. Lancet 2:937CrossRefGoogle Scholar
  23. 23.
    Rosa F (1991) Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 324:674–677PubMedGoogle Scholar
  24. 24.
    Russell AJC, Craig JJ, Morrison P et al. (2004) U.K. epilepsy and pregnancy group. Epilepsia 45:1467CrossRefPubMedGoogle Scholar
  25. 25.
    Samren EB, van Duijn CM, Christiaens GC et al. (1999) Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 46:739–746CrossRefPubMedGoogle Scholar
  26. 26.
    Vinten J, Adab N, Kini U et al. (2005) Neuropsychological effects of exposure to anticonvulsant medication in utero. Neurology 64:949–954PubMedGoogle Scholar
  27. 27.
    Vajda F, Lander C, O’Brien T et al. (2004) Australian pregnancy registry of women taking antiepileptic drugs. Epilepsia 45:1466CrossRefPubMedGoogle Scholar
  28. 28.
    Vajda FJ, Eadie MJ (2005) Maternal valproate dosage and foetal malformations. Acta Neurol Scand 112:137–143CrossRefPubMedGoogle Scholar
  29. 29.
    Waters CH, Belai Y, Gott PS et al. (1994) Outcomes of pregnancy associated with antiepileptic drugs. Arch Neurol 51:250–253PubMedGoogle Scholar
  30. 30.
    Wyszynski DF, Nambisan M, Surve T et al. (2005) Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 64:961–965PubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag 2006

Authors and Affiliations

  1. 1.Abteilung für NeurologieCharité, Universitätsmedizin Berlin, Campus Virchow-KlinikumBerlinDeutschland

Personalised recommendations